title: Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment.
authors: Department of Investigational Cancer Therapeutics (phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. gfalchoo@mdanderson.org
authors: Gerald S
authors: GS
authors: Falchook
authors: Filip
authors: F
authors: Janku
authors: Anne S
authors: AS
authors: Tsao
authors: Christel C
authors: CC
authors: Bastida
authors: David J
authors: DJ
authors: Stewart
authors: Razelle
authors: R
authors: Kurzrock
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D005091:Exons / Q000235:genetics*; D005260:Female; D006801:Humans; D000077341:Lapatinib; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D011379:Prognosis; D011799:Quinazolines / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics*; D000068878:Trastuzumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; D042461:Vascular Endothelial Growth Factor A; C467484:VEGFA protein, human; C508053:ERBB2 protein, human